Spirometry Clinical Trial Eligibility May Differ With Race-Neutral Equations

EMBARGOED UNTIL: 9:15 a.m. PT, May 19, 2024 Spirometry Clinical Trial Eligibility May Differ With Race-Neutral Equations Session: A27 – Emerging Treatments and Therapeutic Strategies in COP: Results of Clinical Trials and Observational Studies Impact of Race-Neutral Spirometry Reference Equations on Eligibility for Chronic Obstructive Pulmonary Disease Clinical Trials Date and Time: Sunday, May 19, 9:15 a.

m. PT Location: San Diego Convention Center, Room 33A-C (Upper Level) Newswise — ATS 2024, San Diego – Equations that don’t use racially and ethnically adjusted spirometry results to help determine eligibility for chronic obstructive pulmonary disease (COPD) clinical trials may lead to higher percentages of Black patients enrolled, according to research published at the ATS 2024 International Conference. “While other researchers have initiated investigations into the effects of adhering to the recent American Thoracic Society (ATS) guidance on utilizing Global Lung Function Initiative (GLI) race-neutral spirometry reference equations in clinical practice, our research has identified a gap in the literature regarding the impact of these equations on inclusion criteria in clinical trials,” said lead author Frank Sciurba, MD, professor of medicine, University of Pittsburgh School of Medicine and medical director, Pulmonary Physiology Lab, UPMC.

In 2023, an expert panel convened by the ATS issued a statement recommending that race and ethnicity no longer be considere.